MTAP and colonic neoplasm: In preclinical tests, MRTX1719 showed robust antiproliferative activity in MTAP-deleted HCT116 colon cancer cells, with an IC50 of 8 nM, compared to an IC50 of 653 nM in WT HCT116 cells, highlighting its over 70-fold selectivity for MTAP-deficient cells.